A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as macrophage receptor with collagenous structure, or MARCO. The findings showed that blocking MARCO in combination with anti-CTLA4 therapy appreciably slows tumor progression in melanoma. The findings were reported in Journal for ImmunoTherapy of Cancer.
Of Interest
Pembrolizumab Plus Bevacizumab Shows Promise for Melanoma Brain Metastases
The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.
New potential nanocarrier cancer vaccine could rescue immune response against melanoma
Researchers have created a new vaccine for the treatment of late-stage metastatic melanoma, an aggressive skin cancer that can resist conventional treatments because it exists in an ecosystem that suppresses the body’s immune response.
Beating the clock: Melanoma starts evading treatment within hours — here’s how to stop it
Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.